FDA advisers backed Moderna’s mRNA flu vaccine, mFlusiva, for adults aged 50 and older. This is an important healthcare headline because it tests whether mRNA can move beyond COVID and become part of the regular seasonal vaccine market.

For Moderna, the catalyst matters because the company needs new revenue streams after COVID vaccine demand slowed. The FDA decision is expected by 5 August 2026. If approved, the vaccine would support the idea that Moderna’s platform can create repeatable revenue outside pandemic products.

Winners

mRNA platform winners

This is the clearest winning group. FDA adviser support improves confidence that mFlusiva can reach the market and gives investors another reason to believe mRNA can work in large, recurring vaccine categories. The impact is not just about one flu shot. It is ab ...